Search

Reportlinker.com announces that a new market research report related to the worldwide pharmaceutical industry is now available to its catalogue. The Global Anti-Infectives Market Outlook to 2011 http://www.reportlinker.com/p051035/anti-infectives .html The [...]

In response to the decision by US drugmaker Abbott Laboratories to boycott Thailand's market for new drugs, itself a reaction to an earlier government decision to issue compulsory licenses against [...]

UK-based GlaxoSmithKline, the world's second-largest drugmaker, has announced further action to help the world's poorest countries meet the unique challenges of HIV/AIDS. In keeping with its commitment to pass on [...]

Open Biosystems, a US firm focused on the commercialization of leading-edge life science research tools for drug discovery, has announced the availability of its lentiviral microRNA-adapted short hairpin RNA (shRNAmir) [...]

Indian drugs giant Ranbaxy Laboratories has introduced two new anti-HIV products, Virolis-E and Virocomb-E. Both products contain three anti-retroviral drugs and offer World Health Organization-recommended first-line highly-active anti-retroviral Therapy in [...]

Four new antiretroviral drugs have been approved for the treatment of AIDS, including Saquinavir, which is one of three approved protease inhibitors. However, medication costs have skyrocketed, leaving over 50% of those with AIDS depending on drug industry programs or public health programs. AIDS therapy can run as high as $18,000 wholesale, while a year's worth of a protease inhibitor costs approximately $5,560., Financial squeeze on AIDS programs threatens access The U.S. Food and Drug Administration's approval in recent weeks of four new antiretroviral drugs, including three protease inhibitors, offers hope to people [...]

With the Oct. 27 FDA approval of Hoffman-La Roche's oral neuraminidase inhibitor Tamiflu, consumers will have the choice between two drugs as the traditional flu season begins. Tamiflu, which was [...]

Pharmacia & Upjohn (P&U), Kalamazoo, Michigan, announced that shipments of Rescriptor tablets (delavirdine mesylate) have been made available at pharmacies throughout the United States. With combination therapy believed to be [...]

On the strength of an international study which recently showed Epivir (lamivudine; 3TC) to be effective in reducing the risk of death and disease progression in persons with AIDS, the [...]

Pharmacia & Upjohn (P&U), London, United Kingdom, announced that the U.S. Food and Drug Administration (FDA) has granted the company marketing clearance for Rescriptor Tablets (delavirdine mesylate tablets), a new [...]

Agouron Pharmaceuticals, Inc., La Jolla, California, has planned to proceed to assemble and file with the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) seeking approval to [...]

SmithKline Beecham, Philadelphia, Pennsylvania, announced that Famvir (famciclovir) is available nationwide to Treat genital herpes. Famvir, an antiviral drug that requires less frequent dosing than the medication commonly used to [...]

DATELINE: Drug Approval Bristol-Myers Squibb Company announced that it has received U.S. Food and Drug Administration (FDA) clearance to market Zerit (stavudine), a new anti -retroviral agent to treat persons [...]

New York Bristol-Myers Squibb Company, New York, New York, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval to [...]

Schering expects 20 million US dollar sales in 1993 from Betaseron, a beta interferon targeted at the treatment of relapsing-remitting multiple sclerosis (MS). For 1994, sales of 200 million US dollars are forecast. The product received FDA approval in July 1993, and it hit the US market in October of the same year. The company plans to invest 860 million Deutsche Marks (DM) in 1994 on R&D, compared to DM800 million in 1993.

ExOxEmis Inc. ExOxEmis, Little Rock, Arkansas, reports to have developed two enzymes, Myeloperoxidase (MPO) and Eosinophil Peroxidase (EPO), trade named Exact, which kill HIV on contact. Jackson T. Stephens Jr., [...]

A new 825-mg formulation of the HIV protease inhibitor Viracept is now available. Patients taking this new version only need to take 2 pills twice daily instead of 5 pills [...]

Despite severe toxicities in up to 5 percent of patients, Glaxo's potent new AIDS drug is poised to enter the market. The drug is abacavir, formerly known by the code [...]

Pharmaceutical joint venture Pasteur Merieux has launched its Avaxin hepatitis A vaccine in the U.K.. The company had been expected to introduce Vaqta, which has received licenses in the U.S. and Germany. Pasteur Merieux's director of business relations says that the two vaccines are very similar.

Wellcome UK has introduced Valtrex, a new antiviral drug and a development of its Zovirax antiviral agent. Valtrex will treat herpes zoster and the company hopes the drug will help it maintain its major share of the antiviral. Valtrex is said to resolve acute shingles pain faster than Zovirax and it has improved bioavailability.